Omega-3 supplements are associated with an increased likelihood of developing atrial fibrillation in people with high blood lipids. That’s the finding of a study published in European Heart Journal - Cardiovascular Pharmacotherapy, a journal of the European Society of Cardiology (ESC).
A chemist from Purdue University has found a way to synthesize a compound to fight a previously "undruggable" cancer protein with benefits across a myriad of cancer types.
The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to a new report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world’s most dangerous bacteria.…
New research by University of Texas at Dallas scientists could help solve a major challenge in the deployment of certain Covid-19 vaccines worldwide — the need for the vaccines to be kept at below-freezing temperatures during transport and storage. In a study published online in Nature Communications, the researchers demonstrate a new, inexpensive technique that generates crystalline…
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, announce that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
A new study by scientists at Kyoto University and the University of Fukui may offer hope for adults who have lost their teeth. The team reports that an antibody for one gene - uterine sensitization associated gene-1 or USAG-1 - can stimulate tooth growth in mice suffering from tooth agenesis, a congenital condition. The paper was published in Science Advances. Although the normal adult mouth has…
Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.…
More than four in five (86%) people who were unsure or said no to a Covid-19 vaccine in December 2020 would now take one, or have already been vaccinated, finds the latest research by the Virus Watch study conducted by University College London (UCL). The new findings, part of UCL Virus Watch’s longitudinal study of over 46,000 people in England and Wales, show the fall in vaccine hesitancy was…
From swallowing pills to injecting insulin, patients frequently administer their own medication. But they don’t always get it right. Improper adherence to doctors’ orders is commonplace, accounting for thousands of deaths and billions of dollars in medical costs annually. Researchers at the Massachusetts Institute of Technology (MIT) have developed a system to reduce those numbers for some…
BOLD-100/KP1339 is a ruthenium-based anticancer agent that has been co-developed at the University of Vienna and which has shown promising results in clinical trials in cancer patients. However, the mode of action of this metal compound has not yet been fully elucidated. Researchers from the University of Vienna and the Medical University of Vienna have now been able to demonstrate that BOLD-100…
A research team of pharmacists at the University of Bonn has discovered two families of active substances that can block the replication of the SARS-CoV-2 coronavirus. The drug candidates are able to switch off the the key enzyme of the virus, the so-called main protease. The study is based on laboratory experiments. Extensive clinical trials are still required for their further development as…
Temperature control equipment and systems company Lauda is expanding its portfolio with its new Versafreeze product line. This consists of high-quality ultra-freezers which have been optimized for the extreme requirements of deep-freeze storage. Lauda thereby meets the requirements of vaccine producers, pharmaceutical service providers, vaccination centers and universities for the safe storage of…
The European Commission has launched a contingency plan to meet the challenge of the various mutations of the coronavirus. Karolinska Institutet and Karolinska University Hospital are contributing to a new network for the evaluation and testing of new vaccines. The network is called "Vaccelerate" and it will contribute both to the evaluation of ongoing and future vaccinations, as well…
Osteoarthritis affects more than 30 million adults and is the fifth-leading cause of disability in the United States. In a new study, scientists have discovered the cellular pathway that leads to the joint disease and have identified a commonly used anti-depressant — paroxetine — that inhibits this pathway.
Is there a better approach to Covid drug research? Research from the University of Kent, Goethe-University in Frankfurt am Main, and the Philipps-University in Marburg has provided crucial insights into the biological composition of SARS-CoV-2, the cause of Covid-19, revealing vital clues for the discovery of antiviral drugs. Researchers compared SARS-CoV-2 and the closely related virus SARS-CoV,…
University of Minnesota Medical School researchers studied SARS-CoV-2 infections at individual cellular levels and made four major discoveries about the virus, including one that validates the effectiveness of remdesivir – an FDA-approved antiviral drug – as a form of treatment for severe Covid-19 disease. “Since the start of the Covid-19 pandemic, the way that each individual responds…
Patients given preventive blood thinning drugs (prophylactic anticoagulants) within 24 hours of admission to hospital with Covid-19 are less likely to die compared with those who do not receive them, a new study finds. Clinical trials are now underway to see if prophylactic anticoagulants could be an effective treatment for Covid-19. In the meantime, the researchers say these findings provide…
One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly published research. “The results provide more justification and rationale for starting the clinical trial in May,” said first author John Mackey, professor and director of oncology clinical…
For the first time, scientists have come up with a precise atomic level explanation for why glulisine - a commonly used medication to treat diabetes - is faster acting than insulin. The findings, published in Scientific Reports, could have benefits for diabetes patients in ensuring that a more improved insulin can be developed for future treatment. The study was carried out by experts from the…
